<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="publisher-id">PLoS</journal-id><journal-id journal-id-type="pmc">plosmed</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Medicine</journal-title></journal-title-group><issn pub-type="epub">1549-1676</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="publisher-id">PMEDICINE-D-10-00644</article-id><article-id pub-id-type="doi">10.1371/journal.pmed.1001022</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Policy Forum</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Drugs and devices</subject>
            <subj-group>
              <subject>Adverse reactions</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Epidemiology</subject>
            <subj-group>
              <subject>Infectious disease epidemiology</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Global health</subject>
          </subj-group>
          <subj-group>
            <subject>Infectious diseases</subject>
            <subj-group>
              <subject>Bacterial diseases</subject>
              <subj-group>
                <subject>Klebsiella infections</subject>
                <subject>Nosocomial infections</subject>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Infectious disease control</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Public health</subject>
            <subj-group>
              <subject>Preventive medicine</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Public Health and Epidemiology</subject>
          <subject>Infectious Diseases</subject>
          <subject>Pharmacology</subject>
        </subj-group>
      </article-categories><title-group><article-title>A Call for Action: The Application of the International Health Regulations to the Global Threat of Antimicrobial Resistance</article-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Wernli</surname>
            <given-names>Didier</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
                        <sup>1</sup>
                    </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Haustein</surname>
            <given-names>Thomas</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
                        <sup>2</sup>
                    </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Conly</surname>
            <given-names>John</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
                        <sup>2</sup>
                    </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Carmeli</surname>
            <given-names>Yehuda</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
                        <sup>3</sup>
                    </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Kickbusch</surname>
            <given-names>Ilona</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
                        <sup>4</sup>
                    </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Harbarth</surname>
            <given-names>Stephan</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
                        <sup>2</sup>
                    </xref>
          <xref ref-type="corresp" rid="cor1">
                        <sup>*</sup>
                    </xref>
        </contrib>
      </contrib-group><aff id="aff1">
                <label>1</label>
                <addr-line>Division of International and Humanitarian Medicine, University of Geneva
                    Hospitals and Faculty of Medicine, Geneva, Switzerland</addr-line>
            </aff><aff id="aff2">
                <label>2</label>
                <addr-line>Infection Control Program, University of Geneva Hospitals and Faculty of
                    Medicine, Geneva, Switzerland</addr-line>
            </aff><aff id="aff3">
                <label>3</label>
                <addr-line>Infection Control Unit, Tel Aviv Sourasky Medical Center, Tel-Aviv,
                    Israel</addr-line>
            </aff><aff id="aff4">
                <label>4</label>
                <addr-line>Global Health Programme, Graduate Institute of International and
                    Development Studies, Geneva, Switzerland</addr-line>
            </aff><author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">stephan.harbarth@hcuge.ch</email></corresp>
        <fn fn-type="con">
          <p>Wrote the first draft: DW TH SH. Wrote the manuscript: DW TH JC YC IK SH.
                        ICMJE criteria for authorship read and met: DW TH YC JC IK SH. Agree with
                        the manuscript's results and conclusions: DW TH YC JC IK SH. Supervised
                        the master′s thesis of DW: IK.</p>
        </fn>
      <fn fn-type="conflict">
        <p>JC has an unpaid relationship with the World Health Organization in the
                    Department of Global Alert and Response (Infection Prevention and Control Unit).
                    All other authors have declared that no competing interests exist.</p>
      </fn></author-notes><pub-date pub-type="collection">
        <month>4</month>
        <year>2011</year>
      </pub-date><pub-date pub-type="epub">
        <day>19</day>
        <month>4</month>
        <year>2011</year>
      </pub-date><volume>8</volume><issue>4</issue><elocation-id>e1001022</elocation-id><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2011</copyright-year><copyright-holder>Wernli et al</copyright-holder><license><license-p>This is an open-access article distributed under the
                terms of the Creative Commons Attribution License, which permits unrestricted use,
                distribution, and reproduction in any medium, provided the original author and
                source are credited.</license-p></license></permissions><related-article id="RA1" issue="4" page="e1001021" related-article-type="companion" vol="8" xlink:href="info:doi/10.1371/journal.pmed.1001021" xlink:title="Research Article" xlink:type="simple">
                <article-title>A Public Health Emergency of International Concern? Response to a
                    Proposal to Apply the International Health Regulations to Antimicrobial
                    Resistance</article-title>
            </related-article><abstract abstract-type="toc">
        <p>Stephen Harbarth and colleagues argue that the International Health Regulations
                    (IHR) should be applied to the global health threat of antimicrobial
                    resistance.</p>
      </abstract><funding-group><funding-statement>The authors received no specific funding to write this paper. JC received
                    financial support for a sabbatical leave from the University of Calgary,
                    Calgary, Canada.</funding-statement></funding-group><counts>
        <page-count count="6"/>
      </counts></article-meta>
  </front>
  <body>
    <boxed-text id="pmed-1001022-box001" position="float">
      <sec id="s1a">
        <title>Summary Points</title>
        <list list-type="bullet">
          <list-item>
            <p>The public health threat of antimicrobial resistance (AMR) is growing and
                            needs to be addressed urgently.</p>
          </list-item>
          <list-item>
            <p>The International Health Regulations (IHR), a legally binding agreement
                            between 194 States Parties, whose aim is to prevent, protect against,
                            control, and provide a public health response to the international
                            spread of disease, deserve critical examination with regard to their
                            applicability to AMR.</p>
          </list-item>
          <list-item>
            <p>We argue that the emergence and spread of antimicrobial-resistant
                            bacteria, especially those involving new pan-resistant strains for which
                            there are no suitable treatments, may constitute a public health
                            emergency of international concern (PHEIC) and are notifiable to the
                            World Health Organization under the IHR notification requirement.</p>
          </list-item>
          <list-item>
            <p>The use of the IHR framework could considerably improve our response to
                            emerging AMR threats like carbapenem-resistant Enterobacteriaceae
                            (CRE).</p>
          </list-item>
          <list-item>
            <p>As more governments start to take the threat of pan-resistant bacteria
                            seriously, there is a window of opportunity for having a healthy debate
                            about the applicability of the IHR to AMR.</p>
          </list-item>
        </list>
      </sec>
    </boxed-text>
    <sec id="s2">
      <title/>
      <p>The unrelenting rise of antimicrobial resistance (AMR) constitutes a serious threat
                to health worldwide. In the last decade, challenging multi-resistant bacteria have
                expanded while new antimicrobial drug development has lagged <xref ref-type="bibr" rid="pmed.1001022-Boucher1">[1]</xref> with little coordinated
                containment action at the global level. Of significant concern has been the
                emergence of vancomycin-resistant <italic>Staphylococcus aureus,</italic>
                extensively drug-resistant (XDR)-tuberculosis, and carbapenem-resistant
                Enterobacteriaceae (CRE).</p>
      <p>AMR in both humans and animals represents a complex global concern that must be
                addressed “urgently and aggressively” <xref ref-type="bibr" rid="pmed.1001022-Nugent1">[2]</xref>. The International Health
                Regulations (IHR), a legally binding agreement between 194 States Parties <xref ref-type="bibr" rid="pmed.1001022-World1">[3]</xref>, deserve critical
                examination with regard to their applicability to AMR. Using the example of CRE as
                point of departure, we analyze and discuss the potential role of the IHR with
                respect to AMR.</p>
    </sec>
    <sec id="s3">
      <title>The Public Health Risk Posed by CRE</title>
      <p>Enterobacteriaceae, a family that includes common pathogens responsible for a large
                spectrum of disease, have been sensitive to many antibiotics in the past. Since the
                1980s, the global spread of extended-spectrum β-lactamase (ESBL)-producing
                Enterobacteriaceae has limited therapeutic options, but until recently, carbapenems
                were still a reliable treatment. The recent emergence of CRE, resistant to most
                classes of antibiotics, has necessitated the use of third-line agents and
                combination therapy with doubtful therapeutic efficacy and increased toxicity <xref ref-type="bibr" rid="pmed.1001022-Nordmann1">[4]</xref>.</p>
      <p><italic>Klebsiella pneumoniae</italic> harboring KPC (KPC-Kp) have become endemic in
                parts of the United States, China, Israel, and Greece <xref ref-type="bibr" rid="pmed.1001022-Nordmann1">[4]</xref>. KPC-Kp have been imported
                from the United States to Israel, and from Israel to Colombia, the United Kingdom,
                and Greece. International spread of KPC-Kp from Greece has occurred to at least nine
                European countries since 2007 with further transmission documented in four of them
                    (<xref ref-type="table" rid="pmed-1001022-t001">Table 1</xref> and <xref ref-type="supplementary-material" rid="pmed.1001022.s001">Figure S1</xref>).
                CRE-producing metallo-β-lactamases of the VIM family have become highly
                prevalent in Greece since their first detection in 2001 and spread to other
                countries in Europe and America <xref ref-type="bibr" rid="pmed.1001022-Vatopoulos1">[5]</xref>. NDM-1-producing CRE likely originated in India or
                Pakistan and have spread to four continents <xref ref-type="bibr" rid="pmed.1001022-Kumarasamy1">[6]</xref>,<xref ref-type="bibr" rid="pmed.1001022-Rolain1">[7]</xref>.</p>
      <table-wrap id="pmed-1001022-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001022.t001</object-id><label>Table 1</label><caption>
          <title>Transmission of carbapenem-resistant <italic>Klebsiella
                            pneumoniae</italic> from Greece to other European countries,
                        2007-2010.</title>
        </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pmed-1001022-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001022.t001" xlink:type="simple"/><table>
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <td align="left" colspan="1" rowspan="1">Country</td>
              <td align="left" colspan="1" rowspan="1">Year</td>
              <td align="left" colspan="1" rowspan="1">Total Number of Patients</td>
              <td align="left" colspan="1" rowspan="1">Origin of Patients</td>
              <td align="left" colspan="1" rowspan="1">Number of Secondary Cases</td>
              <td align="left" colspan="1" rowspan="1">Probability of the Greek Origin</td>
              <td align="left" colspan="1" rowspan="1">References</td>
              <td align="left" colspan="1" rowspan="1">Mechanisms of Resistance</td>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" colspan="1" rowspan="1">
                                <bold>Belgium</bold>
                            </td>
              <td align="left" colspan="1" rowspan="1">2009</td>
              <td align="left" colspan="1" rowspan="1">3</td>
              <td align="left" colspan="1" rowspan="1">3 patients transferred from Greek hospitals</td>
              <td align="left" colspan="1" rowspan="1">0</td>
              <td align="left" colspan="1" rowspan="1">Confirmed</td>
              <td align="left" colspan="1" rowspan="1">Bogaerts et al. 2010 <xref ref-type="bibr" rid="pmed.1001022-Bogaerts1">[19]</xref></td>
              <td align="left" colspan="1" rowspan="1"><italic>bla</italic>KPC-2</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">
                                <bold>Denmark</bold>
                            </td>
              <td align="left" colspan="1" rowspan="1">2009</td>
              <td align="left" colspan="1" rowspan="1">2</td>
              <td align="left" colspan="1" rowspan="1">2 patients transferred from Greek hospitals</td>
              <td align="left" colspan="1" rowspan="1">0</td>
              <td align="left" colspan="1" rowspan="1">Confirmed</td>
              <td align="left" colspan="1" rowspan="1">Hammerum et al. 2010 <xref ref-type="bibr" rid="pmed.1001022-Hammerum1">[20]</xref></td>
              <td align="left" colspan="1" rowspan="1"><italic>bla</italic>KPC-2</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">
                                <bold>Finland</bold>
                            </td>
              <td align="left" colspan="1" rowspan="1">2009</td>
              <td align="left" colspan="1" rowspan="1">1</td>
              <td align="left" colspan="1" rowspan="1">1 patient transferred from Crete</td>
              <td align="left" colspan="1" rowspan="1">0</td>
              <td align="left" colspan="1" rowspan="1">Confirmed</td>
              <td align="left" colspan="1" rowspan="1">Osterblad et al. 2010 <xref ref-type="bibr" rid="pmed.1001022-Osterblad1">[21]</xref></td>
              <td align="left" colspan="1" rowspan="1"><italic>bla</italic>KPC-2</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">
                                <bold>France</bold>
                            </td>
              <td align="left" colspan="1" rowspan="1">No data</td>
              <td align="left" colspan="1" rowspan="1">8</td>
              <td align="left" colspan="1" rowspan="1">1 patient transferred from Crete</td>
              <td align="left" colspan="1" rowspan="1">7</td>
              <td align="left" colspan="1" rowspan="1">Confirmed</td>
              <td align="left" colspan="1" rowspan="1">Naas et al. 2010 <xref ref-type="bibr" rid="pmed.1001022-Naas1">[22]</xref></td>
              <td align="left" colspan="1" rowspan="1"><italic>bla</italic>KPC-2</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">
                                <bold>France</bold>
                            </td>
              <td align="left" colspan="1" rowspan="1">2007</td>
              <td align="left" colspan="1" rowspan="1">1</td>
              <td align="left" colspan="1" rowspan="1">1 patient transferred from Crete</td>
              <td align="left" colspan="1" rowspan="1">0</td>
              <td align="left" colspan="1" rowspan="1">Confirmed</td>
              <td align="left" colspan="1" rowspan="1">Cuzon et al. 2008 <xref ref-type="bibr" rid="pmed.1001022-Cuzon1">[23]</xref></td>
              <td align="left" colspan="1" rowspan="1"><italic>bla</italic>KPC-2</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">
                                <bold>France</bold>
                            </td>
              <td align="left" colspan="1" rowspan="1">2009</td>
              <td align="left" colspan="1" rowspan="1">1</td>
              <td align="left" colspan="1" rowspan="1">1 patient transferred from Greek hospital</td>
              <td align="left" colspan="1" rowspan="1">0</td>
              <td align="left" colspan="1" rowspan="1">Confirmed</td>
              <td align="left" colspan="1" rowspan="1">Barbier et al. 2010 <xref ref-type="bibr" rid="pmed.1001022-Barbier1">[24]</xref></td>
              <td align="left" colspan="1" rowspan="1"><italic>bla</italic>KPC-2</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">
                                <bold>France</bold>
                            </td>
              <td align="left" colspan="1" rowspan="1">2009</td>
              <td align="left" colspan="1" rowspan="1">4</td>
              <td align="left" colspan="1" rowspan="1">1 patient transferred from Greek hospital</td>
              <td align="left" colspan="1" rowspan="1">3</td>
              <td align="left" colspan="1" rowspan="1">Confirmed</td>
              <td align="left" colspan="1" rowspan="1">Kassis-Chikhani et al. 2010 <xref ref-type="bibr" rid="pmed.1001022-KassisChikhani1">[25]</xref></td>
              <td align="left" colspan="1" rowspan="1"><italic>bla</italic>KPC-2</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">
                                <bold>Germany</bold>
                            </td>
              <td align="left" colspan="1" rowspan="1">2007-2008</td>
              <td align="left" colspan="1" rowspan="1">9</td>
              <td align="left" colspan="1" rowspan="1">1 patient treated in Greece</td>
              <td align="left" colspan="1" rowspan="1">8</td>
              <td align="left" colspan="1" rowspan="1">Hypothetical</td>
              <td align="left" colspan="1" rowspan="1">Wendt <italic>et al</italic>. 2010 <xref ref-type="bibr" rid="pmed.1001022-Wendt1">[26]</xref></td>
              <td align="left" colspan="1" rowspan="1"><italic>bla</italic>KPC-2</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">
                                <bold>Hungary</bold>
                            </td>
              <td align="left" colspan="1" rowspan="1">2008</td>
              <td align="left" colspan="1" rowspan="1">7</td>
              <td align="left" colspan="1" rowspan="1">1 patient transferred from Greek hospital</td>
              <td align="left" colspan="1" rowspan="1">6</td>
              <td align="left" colspan="1" rowspan="1">Confirmed</td>
              <td align="left" colspan="1" rowspan="1">Tóth et al. 2010 <xref ref-type="bibr" rid="pmed.1001022-Toth1">[27]</xref></td>
              <td align="left" colspan="1" rowspan="1"><italic>bla</italic>KPC-2</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">
                                <bold>Norway</bold>
                            </td>
              <td align="left" colspan="1" rowspan="1">2007</td>
              <td align="left" colspan="1" rowspan="1">6</td>
              <td align="left" colspan="1" rowspan="1">4 patients transferred from Greek hospitals</td>
              <td align="left" colspan="1" rowspan="1">2</td>
              <td align="left" colspan="1" rowspan="1">Confirmed</td>
              <td align="left" colspan="1" rowspan="1">Samuelson et al. 2009 <xref ref-type="bibr" rid="pmed.1001022-Samuelsen1">[28]</xref></td>
              <td align="left" colspan="1" rowspan="1"><italic>bla</italic>KPC-2</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">
                                <bold>Sweden</bold>
                            </td>
              <td align="left" colspan="1" rowspan="1">No data</td>
              <td align="left" colspan="1" rowspan="1">1</td>
              <td align="left" colspan="1" rowspan="1">1 patient transferred from Greek hospital</td>
              <td align="left" colspan="1" rowspan="1">0</td>
              <td align="left" colspan="1" rowspan="1">Confirmed</td>
              <td align="left" colspan="1" rowspan="1">Tegmark Wisell et al. 2007 <xref ref-type="bibr" rid="pmed.1001022-TegmarkWisell1">[29]</xref></td>
              <td align="left" colspan="1" rowspan="1"><italic>bla</italic>KPC-2</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">
                                <bold>The Netherlands</bold>
                            </td>
              <td align="left" colspan="1" rowspan="1">No data</td>
              <td align="left" colspan="1" rowspan="1">14</td>
              <td align="left" colspan="1" rowspan="1">African immigrants travelling via Greece</td>
              <td align="left" colspan="1" rowspan="1">No data</td>
              <td align="left" colspan="1" rowspan="1">Hypothetical</td>
              <td align="left" colspan="1" rowspan="1">Meessen et al. 2010 <xref ref-type="bibr" rid="pmed.1001022-Meessen1">[30]</xref></td>
              <td align="left" colspan="1" rowspan="1"><italic>bla</italic>KPC-2</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">
                                <bold>The Netherlands</bold>
                            </td>
              <td align="left" colspan="1" rowspan="1">No data</td>
              <td align="left" colspan="1" rowspan="1">1</td>
              <td align="left" colspan="1" rowspan="1">1 patient transferred from Greek hospital</td>
              <td align="left" colspan="1" rowspan="1">No data</td>
              <td align="left" colspan="1" rowspan="1">Confirmed</td>
              <td align="left" colspan="1" rowspan="1">Cohen Stuart et al. 2010 <xref ref-type="bibr" rid="pmed.1001022-CohenStuart1">[31]</xref></td>
              <td align="left" colspan="1" rowspan="1"><italic>bla</italic>KPC-2</td>
            </tr>
          </tbody>
        </table></alternatives></table-wrap>
      <p>CRE have been associated with increased mortality and morbidity, and higher treatment
                costs, when compared to infections caused by susceptible strains <xref ref-type="bibr" rid="pmed.1001022-Schwaber1">[8]</xref>,<xref ref-type="bibr" rid="pmed.1001022-Patel1">[9]</xref>, and have the
                potential to considerably increase the risk associated with routine medical
                procedures. Although CRE have emerged in hospitals, they will eventually spread to
                the community, similar to ESBL-producing Enterobacteriaceae, resulting in
                untreatable common infections in otherwise healthy individuals. CRE, particularly
                NDM-1, are already prevalent in the community in India and Pakistan <xref ref-type="bibr" rid="pmed.1001022-Kumarasamy1">[6]</xref>.</p>
      <p>The alarming spread of CRE is juxtaposed against our failure to develop new effective
                antimicrobials. The utility of tigecycline is marred by high rates of resistance
                among CRE <xref ref-type="bibr" rid="pmed.1001022-Kumarasamy1">[6]</xref>
                and a recent FDA safety warning <xref ref-type="bibr" rid="pmed.1001022-US1">[10]</xref>. The usefulness of colistin, the last drug with reliable
                in vitro activity, is limited by toxicity, moderate efficacy, and emergence of
                resistance <xref ref-type="bibr" rid="pmed.1001022-Kumarasamy1">[6]</xref>. Currently, not a single new agent to treat CRE infections is
                on the horizon. These observations suggest that the international spread of CRE
                constitutes a “cause for worldwide concern” <xref ref-type="bibr" rid="pmed.1001022-Moellering1">[11]</xref>.</p>
    </sec>
    <sec id="s4">
      <title>The Shortcomings of Global AMR Surveillance and Control</title>
      <p>Surveillance of AMR-pathogens such as CRE is patchy and limited by financial and
                technical constraints in large parts of the world. In some high-income countries,
                AMR data are compiled by publicly funded surveillance networks such as EARS-Net, a
                network of national surveillance systems in Europe, or by pharmaceutical
                company-sponsored surveys. Informal networks, such as ProMED, also collect
                information, although selectively and with a considerable time lag. This holds even
                truer for the scientific literature.</p>
      <p>Improving AMR surveillance is one of the key recommendations in a recent report <xref ref-type="bibr" rid="pmed.1001022-Nugent1">[2]</xref>. Without a
                global early warning system, the spread of AMR often remains unnoticed until a given
                strain has become endemic. Although data from Israel indicate that the countrywide
                adoption of enhanced hospital infection control measures was effective in reducing
                endemic KPC-Kp transmission, early proactive surveillance and containment strategies
                are more effective and much less costly <xref ref-type="bibr" rid="pmed.1001022-Schwaber2">[12]</xref>. In view of the shortcomings
                of the current patchwork, a coordinated response using a global framework for
                surveillance and enhanced infection control of CRE and other emerging XDR-pathogens
                is needed.</p>
    </sec>
    <sec id="s5">
      <title>The Potential Role of the IHR</title>
      <p>The IHR provide a legal framework for international efforts to contain the risk from
                public health threats that may spread between countries, including surveillance and
                global alerts (Articles 5–11), definition of core public health capacities for
                surveillance and response in all countries (Articles 5, 13), and World Health
                Organization (WHO) guidance through “standing recommendations” (Articles
                16, 53) <xref ref-type="bibr" rid="pmed.1001022-World1">[3]</xref>.</p>
      <p>In order to identify events that have the “potential to cause international
                disease spread”, WHO is bound to collect epidemiologic information
                “through its surveillance activities” (Article 5), notifications from
                affected countries (Article 6), and reports from third parties (Article 9) <xref ref-type="bibr" rid="pmed.1001022-World1">[3]</xref>. A set of
                criteria defined in Annex 2 of the Regulations (<xref ref-type="fig" rid="pmed-1001022-g001">Figure 1</xref>) is used to determine whether an event
                “may constitute a public health emergency of international
                    concern<italic>”</italic> (PHEIC) and “potentially requires a
                coordinated international response” <xref ref-type="bibr" rid="pmed.1001022-World1">[3]</xref>. The determination of a PHEIC
                constitutes a second and independent step from the notification process and falls
                within the purview of the Director-General of WHO.</p>
      <fig id="pmed-1001022-g001" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pmed.1001022.g001</object-id>
        <label>Figure 1</label>
        <caption>
          <title>International Health Regulations (IHR) 2005 decision instrument for the
                        assessment and notification of events that may constitute a public health
                        emergency of international concern (simplified from Annex 2 of the
                        IHR).</title>
        </caption>
        <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001022.g001" xlink:type="simple"/>
      </fig>
      <p>We argue that certain events marking the emergence and international spread of KPC
                and NDM-1-producing CRE, especially those involving new pan-resistant strains for
                which there are no suitable treatments and which are of major public health
                importance, can be considered to fulfil at least two Annex 2 criteria, in particular
                “serious public health impact” and “international spread”
                    (<xref ref-type="table" rid="pmed-1001022-t002">Table 2</xref>), and should
                therefore be notified to WHO. This argument has, in fact, been made for
                XDR-tuberculosis and can be extrapolated to other types of significant new or
                emerging extensively or pandrug-resistant pathogens such as artemisinin-resistant
                    <italic>Plasmodium falciparum</italic>. “New or emerging antibiotic
                resistance” is one of the examples listed in Annex 2 for application of the
                first criterion.</p>
      <table-wrap id="pmed-1001022-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.1001022.t002</object-id><label>Table 2</label><caption>
          <title>Arguments in favour of and against the applicability of Annex 2 criteria
                        to new CRE events.</title>
        </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pmed-1001022-t002-2" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001022.t002" xlink:type="simple"/><table>
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <td align="left" colspan="1" rowspan="1">Criterion</td>
              <td align="left" colspan="1" rowspan="1">Pro</td>
              <td align="left" colspan="1" rowspan="1">Contra</td>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" colspan="1" rowspan="1">Is the public health impact of the event serious?</td>
              <td align="left" colspan="1" rowspan="1">• The spread of CRE has a high potential for
                                future impact on public health. “Public health impact weighs
                                both the immediate and potential future consequences of an event on
                                the health of human populations” <xref ref-type="bibr" rid="pmed.1001022-World2">[15]</xref>, although it is
                                not clear whether “future” refers to short-term or
                                long-term consequences.• Treatment failure associated with AMR
                                is one of the “circumstances that contribute to high public
                                health impact” listed in Annex 2 <xref ref-type="bibr" rid="pmed.1001022-World1">[3]</xref>.</td>
              <td align="left" colspan="1" rowspan="1">• Not an immediate threat to public health;
                                short-term impact difficult to quantify. The increased attributable
                                morbidity and mortality is mostly restricted to a minority group,
                                i.e., hospitalized patients. Low potential to cause visible
                                community epidemics compared to infections such as influenza,
                                cholera, or polio.</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Is the event unusual or unexpected?</td>
              <td align="left" colspan="1" rowspan="1">• Novel resistance mechanisms, particularly
                                pan-resistance, are by definition unusual and unexpected.</td>
              <td align="left" colspan="1" rowspan="1">• Selection of resistant pathogens is an expected
                                consequence of the use of antimicrobials.</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Is there any significant risk of international
                                spread?</td>
              <td align="left" colspan="1" rowspan="1">• Clear epidemiological links and cross-border
                                movement of individuals colonised or infected with CRE <xref ref-type="bibr" rid="pmed.1001022-Rolain1">[7]</xref>
                                    (<xref ref-type="table" rid="pmed-1001022-t001">Table
                                1</xref>).</td>
              <td align="left" colspan="1" rowspan="1">• The international spread of CRE is slow compared
                                to the acute risk to public health caused by respiratory
                                viruses.</td>
            </tr>
            <tr>
              <td align="left" colspan="1" rowspan="1">Is there any significant risk of international travel
                                or trade restrictions?</td>
              <td align="left" colspan="1" rowspan="1">• In 2008/2009, Russia refused imports of pork and
                                poultry products based on the presence of antibiotic residues <xref ref-type="bibr" rid="pmed.1001022-Johnson1">[32]</xref>; a similar reaction to the presence of
                                CRE in food items would not seem out of the question in the context
                                of increasing concern about AMR.</td>
              <td align="left" colspan="1" rowspan="1">• In reality, no case of trade restrictions and no
                                travel restrictions due to CRE so far.</td>
            </tr>
          </tbody>
        </table></alternatives></table-wrap>
      <p>Still, due to the nonspecific nature of Annex 2 and limited WHO guidance, some may
                counter that CRE (and other AMR) events are irrelevant to the IHR. In a recent
                survey among National IHR Focal Points, a scenario describing a fatal hospital
                outbreak caused by pan-resistant <italic>K. pneumoniae</italic> was considered
                notifiable by just over half of respondents <xref ref-type="bibr" rid="pmed.1001022-Haustein1">[13]</xref>. One of the main arguments
                against applying the IHR to AMR events is that “the IHR are really intended
                for outbreaks of acute disease” <xref ref-type="bibr" rid="pmed.1001022-WHO1">[14]</xref> rather than “acute-on-chronic” events like
                the relatively slow but relentless spread of AMR. However, we would counter that
                this reasoning is inconsistent with the explicitly stated purpose of the IHR
                “to prevent, protect against, control and provide a public health response to
                the international spread of diseases in ways that are commensurate with and
                restricted to public health risks, and which avoid unnecessary interference with
                international traffic and trade”<xref ref-type="bibr" rid="pmed.1001022-World1">[3]</xref>.</p>
      <sec id="s5a">
        <title>Why Should the IHR Be Applied to the Global AMR Threat?</title>
        <p>The global threat posed by the spread of AMR cannot be addressed by individual
                    countries alone, but requires a coordinated international response. Recognizing
                    the applicability of the IHR to AMR will serve as a “wake-up call”
                    and strengthen global AMR surveillance and response, which could in turn
                    contribute to containing the spread of AMR. While WHO has initiated several
                    networks and provides guidance for reporting AMR, including WHONET, none
                    function as an early warning system. Although very few AMR events would be
                    determined a PHEIC by the Director-General, notifications of events that fulfil
                    the Annex 2 criteria could serve as alerts and could be an important instrument
                    in the chain of “the global early warning function, the purpose of which
                    is to provide international support to affected countries and information to
                    other countries if needed” <xref ref-type="bibr" rid="pmed.1001022-World2">[15]</xref>. The immediate consequence of notification is to
                    initiate an “exclusive dialogue between the notifying State Party and WHO
                    concerning the event at issue” <xref ref-type="bibr" rid="pmed.1001022-World2">[15]</xref> and to make a joint risk
                    assessment. Once an event has been notified to WHO, and it is not determined to
                    be a PHEIC, WHO can communicate this information to other countries (Article
                    11). The dissemination of information through the WHO Event Information System
                    (EIS) could expediently increase awareness in multiple countries, allow early
                    implementation of screening measures for persons at risk (e.g., international
                    hospital transfers), and prevent the establishment of new resistant strains in
                    unaffected countries. Based on the experience in Greece and Israel, Carmeli et
                    al. recommend that countries “should be made aware of the problem and
                    should have a preparedness plan ready for implementation at a national
                    level” <xref ref-type="bibr" rid="pmed.1001022-Carmeli1">[16]</xref>. By authorizing WHO to make “standing
                    recommendations” (Article 16), the IHR could facilitate the international
                    dissemination of appropriate measures to counter the spread of AMR.</p>
        <p>Importantly, the IHR focuses on a societal investment in core surveillance and
                    response capacities at different levels by setting minimum standards. WHO
                    pledges to collaborate with the States Parties concerned “by providing
                    technical guidance and assistance and by assessing the effectiveness of the
                    control measure in place, including the mobilization of international teams of
                    experts for on-site assistance, when necessary”. This is relevant for the
                    spread of AMR given the importance of appropriate infection control measures.
                    While details of these measures need to be more closely defined, it is clear
                    that the application of the IHR framework is invaluable for a coordinated global
                    approach to AMR.</p>
      </sec>
      <sec id="s5b">
        <title>What Are the Obstacles to Apply the IHR to the Global Spread of AMR?</title>
        <p>Even if WHO and a majority of States Parties considered that AMR should be
                    addressed under the IHR, technical, financial, and political obstacles might
                    interfere. Notification of an event to WHO depends on it being detected
                    (requiring a functioning health system and adequate laboratory capacities), and
                    reported to the National IHR Focal Point. There is concern that many States
                    Parties are far from being compliant with the IHR's minimum core capacity
                    requirements for surveillance and response. Even if relevant information filters
                    through to the national level, notification decisions may be under political
                    control. The fierce reaction of the Indian government to claims that
                    NDM-1-producing CRE isolated in the UK originated in India casts doubt on the
                    willingness of governments to report the existence of such events, in particular
                    if economic interests (such as the income from medical tourism) are at stake.
                    These obstacles are not specific to AMR-related events, and cannot serve as an
                    argument against the application of the IHR in this context.</p>
        <p>The final obstacles are a lack of expertise and capacities within WHO. Although
                    WHO vertical programs have successfully focused on drug resistance in selected
                    areas, including malaria and tuberculosis, WHO arguably does not have the means
                    to comply with its IHR mandate of offering assistance to States Parties affected
                    by the spread of multi-resistant bacteria. The dearth of leadership in this area
                    was the object of a WHO resolution in 2005, but it has been commented that
                    “very little has taken place to implement the resolution WHA 58.27 since
                    its passage” <xref ref-type="bibr" rid="pmed.1001022-ReAct1">[17]</xref>. During the last World Health Assembly, the Swedish
                    Health Minister commented that “there is an increasing awareness about
                    this major health threat, but far from enough action. The leadership of WHO is
                    urgently needed in this area” <xref ref-type="bibr" rid="pmed.1001022-Larsson1">[18]</xref>.</p>
      </sec>
      <sec id="s5c">
        <title>IHR—A Call for Action</title>
        <p>The IHR do not provide a panacea for the problem of AMR. However, this framework
                    provides a global surveillance infrastructure and orchestrates an appropriate
                    public health response. The IHR are ultimately “owned” by the States
                    Parties, some of whom increasingly understand the extent and urgency of the
                    threat posed by AMR. However, it is up to WHO to provide leadership on the role
                    of the IHR in this matter. Further guidance on the application of Annex 2 to
                    this issue is required. With the IHR in place, increasing the capacities of this
                    framework at all levels to address AMR, rather than investing in new vertical
                    programs, seems logical. The revival of the implementation of the WHO 2001
                    Global Strategy for the containment of AMR with incorporation of the IHR
                    framework into the strategy is required. Although this paradigm shift eventually
                    rests on the World Health Assembly and States Parties' willingness to adopt
                    it, WHO must demonstrate leadership in this regard.</p>
      </sec>
    </sec>
    <sec id="s6">
      <title>Conclusion</title>
      <p>The international dissemination of AMR, typified by CRE, is a serious threat for
                global health. Although the spread of AMR is less dramatic than many acute disease
                outbreaks, it significantly reduces our therapeutic options and adds significantly
                to the health care burden. A global mechanism incorporating both systematic
                surveillance and effective public health response is urgently required. We would
                argue that the IHR provide an appropriate framework to coordinate efforts for
                controlling the international spread of AMR. Several obstacles need attention before
                the full potential of the IHR may be realized, but there is a window of opportunity
                for having a healthy debate about the applicability of the IHR to AMR. While States
                Parties and WHO share a collective responsibility in the process, WHO must clearly
                delineate its position with regard to AMR and the intended role of the IHR in this
                context.</p>
    </sec>
    <sec id="s7">
      <title>Supporting Information</title>
      <supplementary-material id="pmed.1001022.s001" mimetype="image/tiff" position="float" xlink:href="info:doi/10.1371/journal.pmed.1001022.s001" xlink:type="simple">
        <label>Figure S1</label>
        <caption>
          <p>Transmission of carbapenem-resistant <italic>Klebsiella pneumoniae</italic>
                        from Greece to other European countries, 2007–2010</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank Dr. Bruno Coignard (Département de Maladies Infectieuses, Institut de
                Veille Sanitaire, Saint-Maurice, France) for stimulating discussions that helped in
                drafting this review.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pmed.1001022-Boucher1">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Boucher</surname><given-names>HW</given-names></name><name name-style="western"><surname>Talbot</surname><given-names>GH</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>JS</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>JE</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>D</given-names></name><etal/></person-group>
                    <year>2009</year>
                    <article-title>Bad bugs, no drugs: no ESKAPE! An update from the Infectious
                        Diseases Society of America.</article-title>
                    <source>Clin Infect Dis</source>
                    <volume>48</volume>
                    <fpage>1</fpage>
                    <lpage>12</lpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Nugent1">
        <label>2</label>
        <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Nugent</surname><given-names>R</given-names></name><name name-style="western"><surname>Back</surname><given-names>E</given-names></name><name name-style="western"><surname>Beith</surname><given-names>A</given-names></name></person-group>
                    <collab xlink:type="simple">Center for Global Development Drug Resistance Working Group</collab>
                    <year>2010</year>
                    <article-title>The race against drug resistance.</article-title>
                    <publisher-loc>Washington (D.C.)</publisher-loc>
                    <publisher-name>Center for Global Development</publisher-name>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-World1">
        <label>3</label>
        <element-citation publication-type="other" xlink:type="simple">
                    <collab xlink:type="simple">World Health Organization.</collab>
                    <year>2008</year>
                    <article-title>International health regulations (2005).</article-title>
                    <publisher-loc>Geneva</publisher-loc>
                    <publisher-name>World Health Organization</publisher-name>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Nordmann1">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Nordmann</surname><given-names>P</given-names></name><name name-style="western"><surname>Cuzon</surname><given-names>G</given-names></name><name name-style="western"><surname>Naas</surname><given-names>T</given-names></name></person-group>
                    <year>2009</year>
                    <article-title>The real threat of <italic>Klebsiella pneumoniae</italic>
                        carbapenemase-producing bacteria.</article-title>
                    <source>Lancet Infect Dis</source>
                    <volume>9</volume>
                    <fpage>228</fpage>
                    <lpage>236</lpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Vatopoulos1">
        <label>5</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Vatopoulos</surname><given-names>A</given-names></name></person-group>
                    <year>2008</year>
                    <article-title>High rates of metallo-beta-lactamase-producing <italic>Klebsiella
                            pneumoniae</italic> in Greece—a review of the current
                        evidence.</article-title>
                    <source>Euro Surveill</source>
                    <volume>13</volume>
                    <fpage>8023</fpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Kumarasamy1">
        <label>6</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Kumarasamy</surname><given-names>KK</given-names></name><name name-style="western"><surname>Toleman</surname><given-names>MA</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>TR</given-names></name><name name-style="western"><surname>Bagaria</surname><given-names>J</given-names></name><name name-style="western"><surname>Butt</surname><given-names>F</given-names></name><etal/></person-group>
                    <year>2010</year>
                    <article-title>Emergence of a new antibiotic resistance mechanism in India,
                        Pakistan, and the UK: a molecular, biological, and epidemiological
                        study.</article-title>
                    <source>Lancet Infect Dis</source>
                    <volume>10</volume>
                    <fpage>597</fpage>
                    <lpage>602</lpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Rolain1">
        <label>7</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Rolain</surname><given-names>JM</given-names></name><name name-style="western"><surname>Parola</surname><given-names>P</given-names></name><name name-style="western"><surname>Cornaglia</surname><given-names>G</given-names></name></person-group>
                    <year>2010</year>
                    <article-title>New Delhi metallo-beta-lactamase (NDM-1): towards a new
                        pandemia?</article-title>
                    <source>Clin Microbiol Infect</source>
                    <volume>12</volume>
                    <fpage>1699</fpage>
                    <lpage>1701</lpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Schwaber1">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Schwaber</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Klarfeld-Lidji</surname><given-names>S</given-names></name><name name-style="western"><surname>Navon-Venezia</surname><given-names>S</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>D</given-names></name><name name-style="western"><surname>Leavitt</surname><given-names>A</given-names></name><etal/></person-group>
                    <year>2008</year>
                    <article-title>Predictors of carbapenem-resistant <italic>Klebsiella
                            pneumoniae</italic> acquisition among hospitalized adults and effect of
                        acquisition on mortality.</article-title>
                    <source>Antimicrob Agents Chemother</source>
                    <volume>52</volume>
                    <fpage>1028</fpage>
                    <lpage>1033</lpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Patel1">
        <label>9</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>G</given-names></name><name name-style="western"><surname>Huprikar</surname><given-names>S</given-names></name><name name-style="western"><surname>Factor</surname><given-names>SH</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>SG</given-names></name><name name-style="western"><surname>Calfee</surname><given-names>DP</given-names></name></person-group>
                    <year>2008</year>
                    <article-title>Outcomes of carbapenem-resistant <italic>Klebsiella
                            pneumoniae</italic> infection and the impact of antimicrobial and
                        adjunctive therapies.</article-title>
                    <source>Infect Control Hosp Epidemiol</source>
                    <volume>29</volume>
                    <fpage>1099</fpage>
                    <lpage>1106</lpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-US1">
        <label>10</label>
        <element-citation publication-type="other" xlink:type="simple">
                    <collab xlink:type="simple">US Food and Drug Administration</collab>
                    <year>2010</year>
                    <comment>FDA drug safety communication: increased risk of death with Tygacil
                        (tigecycline) compared to other antibiotics used to treat similar
                        infections. Available: <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm" xlink:type="simple">http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm</ext-link>. Accessed
                        14 March 2011</comment>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Moellering1">
        <label>11</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Moellering</surname><given-names>RC</given-names></name></person-group>
                    <year>2010</year>
                    <article-title>NDM-1—a cause for worldwide concern.</article-title>
                    <source>New Eng J Med</source>
                    <volume>363</volume>
                    <fpage>2377</fpage>
                    <lpage>2379</lpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Schwaber2">
        <label>12</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Schwaber</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Lev</surname><given-names>B</given-names></name><name name-style="western"><surname>Israeli</surname><given-names>A</given-names></name><name name-style="western"><surname>Solter</surname><given-names>E</given-names></name><name name-style="western"><surname>Smollan</surname><given-names>G</given-names></name><etal/></person-group>
                    <year>2011</year>
                    <article-title>Containment of a country-wide outbreak of carbapenem-resistant
                            <italic>Klebsiella pneumoniae</italic> in Israeli hospitals via a
                        nationally-implemented intervention.</article-title>
                    <source>Clin Infect Dis</source>
                    <volume>52</volume>
                    <fpage>1</fpage>
                    <lpage>8</lpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Haustein1">
        <label>13</label>
        <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Haustein</surname><given-names>T</given-names></name><name name-style="western"><surname>Hollmeyer</surname><given-names>H</given-names></name><name name-style="western"><surname>Hardiman</surname><given-names>M</given-names></name><name name-style="western"><surname>Harbarth</surname><given-names>S</given-names></name><name name-style="western"><surname>Pittet</surname><given-names>D</given-names></name></person-group>
                    <year>2011</year>
                    <article-title>Should this event be notified to WHO?</article-title>
                    <publisher-loc>Reliability of the International Health Regulations notification
                        assessment process. Bull WHO</publisher-loc>
                    <publisher-name>In press</publisher-name>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-WHO1">
        <label>14</label>
        <element-citation publication-type="other" xlink:type="simple">
                    <collab xlink:type="simple">WHO Global Task Force on XDR-TB</collab>
                    <year>2007</year>
                    <article-title>Report of the meeting of the WHO Global Task Force on XDR-TB,
                        9-10 October 2006.</article-title>
                    <publisher-loc>Geneva</publisher-loc>
                    <publisher-name>World Health Organization</publisher-name>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-World2">
        <label>15</label>
        <element-citation publication-type="other" xlink:type="simple">
                    <collab xlink:type="simple">World Health Organization</collab>
                    <year>2008</year>
                    <article-title>WHO guidance for the use of Annex 2 of the International Health
                        Regulations (2005).</article-title>
                    <publisher-loc>Geneva</publisher-loc>
                    <publisher-name>World Health Organization</publisher-name>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Carmeli1">
        <label>16</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Carmeli</surname><given-names>Y</given-names></name><name name-style="western"><surname>Akova</surname><given-names>M</given-names></name><name name-style="western"><surname>Cornaglia</surname><given-names>G</given-names></name><name name-style="western"><surname>Daikos</surname><given-names>GL</given-names></name><name name-style="western"><surname>Garau</surname><given-names>J</given-names></name><etal/></person-group>
                    <year>2010</year>
                    <article-title>Controlling the spread of carbapenemase-producing Gram-negatives:
                        therapeutic approach and infection control.</article-title>
                    <source>Clin Microbiol Infect</source>
                    <volume>16</volume>
                    <fpage>102</fpage>
                    <lpage>111</lpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-ReAct1">
        <label>17</label>
        <element-citation publication-type="other" xlink:type="simple">
                    <collab xlink:type="simple">ReAct</collab>
                    <year>2007</year>
                    <article-title>Antibiotic resistance - a call for global
                        leadership.</article-title>
                    <comment>Available: <ext-link ext-link-type="uri" xlink:href="http://soapimg.icecube.snowfall.se/stopresistance/ReAct_response.pdf" xlink:type="simple">http://soapimg.icecube.snowfall.se/stopresistance/ReAct_response.pdf</ext-link>.
                        Accessed 14 March 2011</comment>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Larsson1">
        <label>18</label>
        <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Larsson</surname><given-names>M</given-names></name></person-group>
                    <year>2010</year>
                    <article-title>Discourse at the the World Health Assembly.</article-title>
                    <comment>Available: <ext-link ext-link-type="uri" xlink:href="http://www.regeringen.se/sb/d/12546/a/146073" xlink:type="simple">http://www.regeringen.se/sb/d/12546/a/146073</ext-link>. Accessed 14
                        March 2011</comment>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Bogaerts1">
        <label>19</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Bogaerts</surname><given-names>P</given-names></name><name name-style="western"><surname>Montesinos</surname><given-names>I</given-names></name><name name-style="western"><surname>Rodriguez-Villalobos</surname><given-names>H</given-names></name><name name-style="western"><surname>Blairon</surname><given-names>L</given-names></name><name name-style="western"><surname>Deplano</surname><given-names>A</given-names></name><etal/></person-group>
                    <year>2010</year>
                    <article-title>Emergence of clonally related <italic>Klebsiella
                            pneumoniae</italic> isolates of sequence type 258 producing KPC-2
                        carbapenemase in Belgium.</article-title>
                    <source>J Antimicrob Chemother</source>
                    <volume>65</volume>
                    <fpage>361</fpage>
                    <lpage>362</lpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Hammerum1">
        <label>20</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Hammerum</surname><given-names>AM</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>F</given-names></name><name name-style="western"><surname>Lester</surname><given-names>CH</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>KT</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>DS</given-names></name><etal/></person-group>
                    <year>2010</year>
                    <article-title>Detection of the first two <italic>Klebsiella pneumoniae</italic>
                        isolates with sequence type 258 producing KPC-2 carbapenemase in
                        Denmark.</article-title>
                    <source>Int J Antimicrob Agents</source>
                    <volume>35</volume>
                    <fpage>610</fpage>
                    <lpage>612</lpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Osterblad1">
        <label>21</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Osterblad</surname><given-names>M</given-names></name><name name-style="western"><surname>Kirveskari</surname><given-names>J</given-names></name><name name-style="western"><surname>Koskela</surname><given-names>S</given-names></name><name name-style="western"><surname>Tissari</surname><given-names>P</given-names></name><name name-style="western"><surname>Vuorenoja</surname><given-names>K</given-names></name><etal/></person-group>
                    <year>2009</year>
                    <article-title>First isolations of KPC-2-carrying ST258 <italic>Klebsiella
                            pneumoniae</italic> strains in Finland, June and August
                        2009.</article-title>
                    <source>Euro Surveill</source>
                    <volume>14</volume>
                    <fpage>19349</fpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Naas1">
        <label>22</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Naas</surname><given-names>T</given-names></name><name name-style="western"><surname>Cuzon</surname><given-names>G</given-names></name><name name-style="western"><surname>Babics</surname><given-names>A</given-names></name><name name-style="western"><surname>Fortineau</surname><given-names>N</given-names></name><name name-style="western"><surname>Boytchev</surname><given-names>I</given-names></name><etal/></person-group>
                    <year>2010</year>
                    <article-title>Endoscopy-associated transmission of carbapenem-resistant
                            <italic>Klebsiella pneumoniae</italic> producing KPC-2
                        {beta}-lactamase.</article-title>
                    <source>J Antimicrob Chemother</source>
                    <volume>65</volume>
                    <fpage>1305</fpage>
                    <lpage>1306</lpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Cuzon1">
        <label>23</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Cuzon</surname><given-names>G</given-names></name><name name-style="western"><surname>Naas</surname><given-names>T</given-names></name><name name-style="western"><surname>Demachy</surname><given-names>MC</given-names></name><name name-style="western"><surname>Nordmann</surname><given-names>P</given-names></name></person-group>
                    <year>2008</year>
                    <article-title>Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in
                            <italic>Klebsiella pneumoniae</italic> isolate from
                        Greece.</article-title>
                    <source>Antimicrob Agents Chemother</source>
                    <volume>52</volume>
                    <fpage>796</fpage>
                    <lpage>797</lpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Barbier1">
        <label>24</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Barbier</surname><given-names>F</given-names></name><name name-style="western"><surname>Ruppe</surname><given-names>E</given-names></name><name name-style="western"><surname>Giakkoupi</surname><given-names>P</given-names></name><name name-style="western"><surname>Wildenberg</surname><given-names>L</given-names></name><name name-style="western"><surname>Lucet</surname><given-names>J</given-names></name><etal/></person-group>
                    <year>2010</year>
                    <article-title>Genesis of a KPC-producing <italic>Klebsiella pneumoniae</italic>
                        after in vivo transfer from an imported Greek strain.</article-title>
                    <source>Euro Surveill</source>
                    <volume>15</volume>
                    <fpage>19457</fpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-KassisChikhani1">
        <label>25</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Kassis-Chikhani</surname><given-names>N</given-names></name><name name-style="western"><surname>Decre</surname><given-names>D</given-names></name><name name-style="western"><surname>Ichai</surname><given-names>P</given-names></name><name name-style="western"><surname>Sengelin</surname><given-names>C</given-names></name><name name-style="western"><surname>Geneste</surname><given-names>D</given-names></name><etal/></person-group>
                    <year>2010</year>
                    <article-title>Outbreak of <italic>Klebsiella pneumoniae</italic> producing
                        KPC-2 and SHV-12 in a French hospital.</article-title>
                    <source>J Antimicrob Chemother</source>
                    <volume>65</volume>
                    <fpage>1539</fpage>
                    <lpage>1540</lpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Wendt1">
        <label>26</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Wendt</surname><given-names>C</given-names></name><name name-style="western"><surname>Schutt</surname><given-names>S</given-names></name><name name-style="western"><surname>Dalpke</surname><given-names>AH</given-names></name><name name-style="western"><surname>Konrad</surname><given-names>M</given-names></name><name name-style="western"><surname>Mieth</surname><given-names>M</given-names></name><etal/></person-group>
                    <year>2010</year>
                    <article-title>First outbreak of <italic>Klebsiella pneumoniae</italic>
                        carbapenemase (KPC)-producing <italic>K. pneumoniae</italic> in
                        Germany.</article-title>
                    <source>Eur J Clin Microbiol Infect Dis</source>
                    <volume>29</volume>
                    <fpage>563</fpage>
                    <lpage>570</lpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Toth1">
        <label>27</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Toth</surname><given-names>A</given-names></name><name name-style="western"><surname>Damjanova</surname><given-names>I</given-names></name><name name-style="western"><surname>Puskas</surname><given-names>E</given-names></name><name name-style="western"><surname>Janvari</surname><given-names>L</given-names></name><name name-style="western"><surname>Farkas</surname><given-names>M</given-names></name><etal/></person-group>
                    <year>2010</year>
                    <article-title>Emergence of a colistin-resistant KPC-2-producing
                            <italic>Klebsiella pneumoniae</italic> ST258 clone in
                        Hungary.</article-title>
                    <source>Eur J Clin Microbiol Infect Dis</source>
                    <volume>29</volume>
                    <fpage>765</fpage>
                    <lpage>769</lpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Samuelsen1">
        <label>28</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Samuelsen</surname><given-names>O</given-names></name><name name-style="western"><surname>Naseer</surname><given-names>U</given-names></name><name name-style="western"><surname>Tofteland</surname><given-names>S</given-names></name><name name-style="western"><surname>Skutlaberg</surname><given-names>DH</given-names></name><name name-style="western"><surname>Onken</surname><given-names>A</given-names></name><etal/></person-group>
                    <year>2009</year>
                    <article-title>Emergence of clonally related <italic>Klebsiella
                            pneumoniae</italic> isolates of sequence type 258 producing
                        plasmid-mediated KPC carbapenemase in Norway and Sweden.</article-title>
                    <source>J Antimicrob Chemother</source>
                    <volume>63</volume>
                    <fpage>654</fpage>
                    <lpage>658</lpage>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-TegmarkWisell1">
        <label>29</label>
        <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Tegmark Wisell</surname><given-names>K</given-names></name><name name-style="western"><surname>Haeggman</surname><given-names>S</given-names></name><name name-style="western"><surname>Gezelius</surname><given-names>L</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>O</given-names></name><name name-style="western"><surname>Gustafsson</surname><given-names>I</given-names></name><etal/></person-group>
                    <year>2007</year>
                    <article-title>Identification of <italic>Klebsiella pneumoniae</italic>
                        carbapenemase in Sweden.</article-title>
                    <source>Euro Surveill 12: E071220</source>
                    <volume>071223</volume>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Meessen1">
        <label>30</label>
        <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Meessen</surname><given-names>N</given-names></name><name name-style="western"><surname>Wiersinga</surname><given-names>J</given-names></name><name name-style="western"><surname>van der Zwaluw</surname><given-names>K</given-names></name><name name-style="western"><surname>van Altena</surname><given-names>R</given-names></name></person-group>
                    <year>2010</year>
                    <article-title>First outbreak of carbapenemase-producing <italic>Klebsiella
                            pneumoniae</italic> in a tuberculosis care facility in the Netherlands.
                        Abstract number: P1283. Proceedings of the 20th European Congress of
                        Clinical Microbiology and Infectious Diseases (ECCMID); 10 April–13
                        April, 2010; Vienna, Austria.</article-title>
                    <comment>Available: <ext-link ext-link-type="uri" xlink:href="http://registration.akm.ch/2010eccmid_einsicht.php?XNABSTRACT_ID=104079&amp;XNSPRACHE_ID=2&amp;XNKONGRESS_ID=114&amp;XNMASKEN_ID=900" xlink:type="simple">http://registration.akm.ch/2010eccmid_einsicht.php?XNABSTRACT_ID=104079&amp;XNSPRACHE_ID=2&amp;XNKONGRESS_ID=114&amp;XNMASKEN_ID=900</ext-link>.
                        Accessed 14 March 2011</comment>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-CohenStuart1">
        <label>31</label>
        <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Cohen Stuart</surname><given-names>JW</given-names></name><name name-style="western"><surname>Voets</surname><given-names>G</given-names></name><name name-style="western"><surname>Versteeg</surname><given-names>D</given-names></name><name name-style="western"><surname>Scharringa</surname><given-names>J</given-names></name><name name-style="western"><surname>Tersmette</surname><given-names>M</given-names></name><etal/></person-group>
                    <year>2010</year>
                    <article-title>The first carbapenemase-producing <italic>Klebsiella
                            pneumoniae</italic> strains in the Netherlands are associated with
                        international travel. Abstract number: P1284. Proceedings of the 20th
                        European Congress of Clinical Microbiology and Infectious Diseases (ECCMID);
                        10 April–13 April, 2010; Vienna, Austria.</article-title>
                    <comment>Available: <ext-link ext-link-type="uri" xlink:href="http://registration.akm.ch/2010eccmid_einsicht.php?XNABSTRACT_ID=103461&amp;XNSPRACHE_ID=2&amp;XNKONGRESS_ID=114&amp;XNMASKEN_ID=900" xlink:type="simple">http://registration.akm.ch/2010eccmid_einsicht.php?XNABSTRACT_ID=103461&amp;XNSPRACHE_ID=2&amp;XNKONGRESS_ID=114&amp;XNMASKEN_ID=900</ext-link>.
                        Accessed 14 March 2011</comment>
                </element-citation>
      </ref>
      <ref id="pmed.1001022-Johnson1">
        <label>32</label>
        <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>R</given-names></name><name name-style="western"><surname>Becker</surname><given-names>G</given-names></name></person-group>
                    <year>2010</year>
                    <article-title>US-Russia meat and poultry trade issues. Washington (D.C.):
                        Congressional Research Service for Congress.</article-title>
                    <comment>Available: <ext-link ext-link-type="uri" xlink:href="http://www.nationalaglawcenter.org/assets/crs/RS22948.pdf" xlink:type="simple">http://www.nationalaglawcenter.org/assets/crs/RS22948.pdf</ext-link>.
                        Accessed 14 March 2011</comment>
                </element-citation>
      </ref>
    </ref-list>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>AMR</term>
          <def>
            <p>antimicrobial resistance</p>
          </def>
        </def-item>
        <def-item>
          <term>CRE</term>
          <def>
            <p>carbapenem-resistant Enterobacteriaceae</p>
          </def>
        </def-item>
        <def-item>
          <term>IHR</term>
          <def>
            <p>International Health Regulations</p>
          </def>
        </def-item>
        <def-item>
          <term>KPC-Kp</term>
          <def>
            <p><italic>Klebsiella pneumoniae</italic> harboring KPC</p>
          </def>
        </def-item>
        <def-item>
          <term>PHEIC</term>
          <def>
            <p>public health emergency of international concern</p>
          </def>
        </def-item>
        <def-item>
          <term>WHO</term>
          <def>
            <p>World Health Organization</p>
          </def>
        </def-item>
        <def-item>
          <term>XDR</term>
          <def>
            <p>extensively drug-resistant</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group><fn fn-type="other">
        <p><bold>Provenance:</bold> Not commissioned; externally peer reviewed.</p>
      </fn></fn-group>
  </back>
</article>